Trial Outcomes & Findings for Using Information Technology to Improve Asthma Adherence (NCT NCT00459368)
NCT ID: NCT00459368
Last Updated: 2010-08-17
Results Overview
Adherence to ICS medication was measured during the last 3 months of the intervention (i.e., for the time period of 9-12 months post-randomization). Adherence was measured using pharmacy claims data, and represents the percent of prescribed medication taken. The normal range for this value is 0-100%.
COMPLETED
NA
2698 participants
1 year
2010-08-17
Participant Flow
Health system primary care providers (i.e., in the areas of family practice, internal medicine, and pediatrics) were invited to participate. Physicians who consented to participate were grouped according to practice.
One hundred ninety-two (92%) of the 207 primary care staff clinicians, representing 34 pre-defined primary care practices within the health system, agreed to participate. One clinic was not included a priori since it functioned as the primary resident clinic for internal medicine trainees.
Participant milestones
| Measure |
Patient Medication Adherence Feedback
In this cluster-randomized trial physicians practicing at intervention clinic sites will receive adherence information on their patients with asthma who are currently taking an inhaled corticosteroid medication. This information will be available to them via our electronic prescribing software to discuss with patients at the time of the visit. Physicians at these sites also receive standardized training in how to interpret and intervene when poor adherence is identified.
|
Usual Care
Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
|
|---|---|---|
|
Overall Study
STARTED
|
1335
|
1363
|
|
Overall Study
COMPLETED
|
1040
|
1034
|
|
Overall Study
NOT COMPLETED
|
295
|
329
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Using Information Technology to Improve Asthma Adherence
Baseline characteristics by cohort
| Measure |
Patient Medication Adherence Feedback
n=1335 Participants
In this cluster-randomized trial physicians practicing at intervention clinic sites will receive adherence information on their patients with asthma who are currently taking an inhaled corticosteroid medication. This information will be available to them via our electronic prescribing software to discuss with patients at the time of the visit. Physicians at these sites also receive standardized training in how to interpret and intervene when poor adherence is identified.
|
Usual Care
n=1363 Participants
Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
|
Total
n=2698 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
591 Participants
n=5 Participants
|
604 Participants
n=7 Participants
|
1195 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
744 Participants
n=5 Participants
|
759 Participants
n=7 Participants
|
1503 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age Continuous
|
25.6 years
STANDARD_DEVIATION 37.3 • n=5 Participants
|
27.7 years
STANDARD_DEVIATION 38.5 • n=7 Participants
|
26.6 years
STANDARD_DEVIATION 37.9 • n=5 Participants
|
|
Sex: Female, Male
Female
|
737 Participants
n=5 Participants
|
753 Participants
n=7 Participants
|
1490 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
598 Participants
n=5 Participants
|
610 Participants
n=7 Participants
|
1208 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
1335 participants
n=5 Participants
|
1363 participants
n=7 Participants
|
2698 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 1 yearAdherence to ICS medication was measured during the last 3 months of the intervention (i.e., for the time period of 9-12 months post-randomization). Adherence was measured using pharmacy claims data, and represents the percent of prescribed medication taken. The normal range for this value is 0-100%.
Outcome measures
| Measure |
Patient Medication Adherence Feedback
n=1335 Participants
In this cluster-randomized trial physicians practicing at intervention clinic sites will receive adherence information on their patients with asthma who are currently taking an inhaled corticosteroid medication. This information will be available to them via our electronic prescribing software to discuss with patients at the time of the visit. Physicians at these sites also receive standardized training in how to interpret and intervene when poor adherence is identified.
|
Usual Care
n=1363 Participants
Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
|
|---|---|---|
|
Patient Adherence to Inhaled Corticosteroids (ICS)
|
21.3 Percent of ICS medication taken
Standard Deviation 2.5
|
23.3 Percent of ICS medication taken
Standard Deviation 2.2
|
SECONDARY outcome
Timeframe: 1 yearOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 1 yearOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 1 yearOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: survey following intervention periodOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: survey following intervention periodOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: survey following intervention periodOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 1 yearOutcome measures
Outcome data not reported
Adverse Events
Patient Medication Adherence Feedback
Usual Care
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
L. Keoki Williams, MD, MPH
Henry Ford Health System
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place